Benitec settles another lawsuit

By Melissa Trudinger
Tuesday, 24 August, 2004

RNAi company Benitec (ASX: BLT) has settled its second patent infringement lawsuit in two weeks, giving US company Genscript Corporation a non-exclusive worldwide licence to manufacture and sell DNA-directed RNAi (ddRNAi) products.

The lawsuit was one of three filed on March 22, 2004 against US companies Ambion, Genscript and Nucleonics. Ambion was granted a licence as part of a settlement announced on August 10. Financial details of the settlement and licence were not disclosed.

The company has also been granted a second UK patent related to its ddRNAi technology for use of ddRNAi expressed as hairpins in vertebrate animal cells, bringing the number of issued patents in the company's portfolio to eight.

Related News

Hormone therapy shifts body proteins to match gender identity

Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...

Targeting 'molecular bodyguards' weakens prostate cancer cells

Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...

Females found to carry a higher genetic risk of depression

An international team of scientists has discovered about twice as many genetic 'flags'...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd